

## I. AMENDMENTS

In the claims:

Please amend claims 1 and 3, as follows:

1. (Amended) A process for preparing a biologically active fraction designated ASB03 from a composition of *Scutellariae barbatae* comprising extracting from a filtrate, a fraction soluble in an organic solvent wherein said fraction has an optical absorbance between about 200nm to about 500nm.
2. (Reiterated) The process of claim 1, comprising the steps of:
- a) steeping an effective amount of *Scutellariae barbatae* in an effective amount of hot water to obtain a liquid extract;
  - b) filtering the extract to obtain a filtrate designated ESBa;
  - c) extracting the filtrate with an effective amount of an organic solvent to obtain ESBb;
  - d) concentrating the extract; and
  - e) isolating a fraction having an optical absorbance at about 200 nm to about 450 nm to isolate ASB03.
3. (Amended) The process of claim 1, comprising the steps of:
- a) obtaining a ~~supernatant by extracting at least two times with ethanol from a~~ liquid extract of *Scutellariae barbatae* and obtaining a supernatant by extracting the liquid extract at least two times with ethanol;
  - b) obtaining a concentrated supernatant by extracting the supernatant at least three times with methanol;
  - c) evaporating the methanol with nitrogen gas;
  - d) resuspending the extract in about 12 to about 18 ml of water and drying;
  - e) resuspending the dried extract in a pharmaceutically acceptable carrier to form a solution;

- f) running the solution over a C-18 mini-column;
- g) washing the column with at least about 35 ml of water;
- h) washing the column with at least 15 ml of 25% methanol;
- i) evaporating the methanol with nitrogen gas;
- j) resuspending the extract in a liquid carrier; and
- k) obtaining the active fraction by a C-18 hydrophobic HPLC

chromatography to obtain a biologically active extract designated ASB03 having an optical absorbance from about 200 nm to about 500nm.

4. (Reiterated) A biologically active extract obtained by the process of claim 1.

5. (Reiterated) A composition comprising the extract of claim 4 and a pharmaceutically acceptable carrier.

B<sup>1</sup>  
6. (Reiterated) A composition comprising the extract of claim 4 and an anti-angiogenic or immunostimulatory agent.

Claims 7 to 18 and 21 (Withdrawn)

19. (Reiterated) A kit for treating a disorder associated with pathological neovascularization in a host, comprising a therapeutically effective amount of the extract of claim 4 and instructions for use.

20. (Reiterated) The kit of claim 19, wherein the disorder is selected from the group consisting of cancer, arthritic conditions, neovascular-based dermatological conditions, diabetic retinopathy, Kaposi's Sarcoma, age-related macular degeneration, restinosis, telangiectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma, Osler-Webber Syndrome, myocardial angiogenesis, and scleroderma.

---